Publications
470
Citations
17,234
Est. group size
—
Recurring co-author estimate
Active years
34
Publishing since 1993
Bert H. O'Neil conducts clinical cancer research (oncology), focusing on testing new drugs and treatment strategies for solid tumors in human clinical trials. Much of the work involves gastrointestinal cancers (such as colorectal, gastric, pancreatic, and liver cancers) as well as early-phase 'first-in-human' studies of novel targeted therapies and antibody-based drugs. The research emphasizes evaluating the safety, effectiveness, and biological markers of response for emerging cancer treatments.
Publication activity has fluctuated over the last decade, with high output in some years (48 in 2017, 61 in 2023) and lower counts in others, averaging about 22 publications per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study
Clinical Lung Cancer · 2026
- Supplementary Figure S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Supplementary Figure S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Supplementary Figure S5 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Supplementary Table S2 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Supplementary Table S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Data from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Supplementary Table S1 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Supplementary Figure S4 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Supplementary Figure S3 from Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
2026
- Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Clinical Cancer Research · 2025
- Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors
Cancer Research · 2025
- Preliminary results from a first-in-human, phase I/II study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced solid tumors.
Journal of Clinical Oncology · 2025
- Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan.
Journal of Clinical Oncology · 2025
- Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
European Journal of Cancer · 2025
- Journal of Clinical Oncology×67
- UNC Libraries×25
- Annals of Oncology×19
- Cancer Research×9
- Clinical Cancer Research×8
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile